Luci Berardi had known for three months that something was wrong. As a yoga practitioner and instructor, she was very much in tune with her body, and the changes she was noticing were odd and disconcerting.
First there was the … Read more
For patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.
By Kristi Rosa
For patients with recurrent platinum-resistant epithelial
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more
Ovarian cancer is a serious gynecologic cancer and the fifth leading cause of cancer-related deaths among women in the United States.1 To minimize the risk of the coronavirus disease (COVID-19) transmission while … Read more
Ixabepilone plus bevacizumab yielded responses in a third of patients.
By Ian Ingram
Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.
Median progression-free … Read more
Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study.
By Charles Bankhead
Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.
Median progression-free survival (PFS) doubled … Read more
October of 2019, I had my initial tumor removal via an oophorectomy. My oncologist was extremely empathetic and insisted that all measures would be taken to preserve my fertility given my age. However, on November 13, 2019, three weeks following … Read more
By Chase Doyle
The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more
By Chase Doyle
Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more
Responses in 37% of patients with AVB-500, higher without prior bevacizumab.
By Charles Bankhead
More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more
Although some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due … Read more
Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.
By Charles Bankhead
A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.
Treatment with rucaparib (Rubraca) … Read more
High tumor mutational burden (TMB) was useful for predicting clinical responses to immune checkpoint inhibitors only in a subset of cancer types, according to a study published by McGrail et al in Annals of Oncology.
The findings suggest that … Read more
By R. Colon-Thillet
Treatment for ovarian cancer across subtypes typically consists of platinum-based chemotherapies. However, this standard therapy is less effective against ovarian clear cell carcinoma (OCCC), a rare subtype of ovarian cancer with distinct pathology and genetic drivers. Advanced … Read more
By Lisa Rapaport
Patients with cancer shouldn’t delay COVID-19 vaccination despite the potential for clinically evident adenopathy on imaging done after vaccination, according to recommendations from a multidisciplinary panel of scientific experts.
Vaccination-associated adenopathy or axillary swelling may appear within … Read more
The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.
By Courtney Marabella
The FDA has granted priority review to the new
By Christina Bennett, MS
The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing. Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results … Read more
For cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more
An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.
By Courtney Marabella… Read more
By Matthew Stenger
In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease … Read more
